Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use

7/15/24 8:03:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HRTX alert in real time by email

Get the next $HRTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HRTX

Date	Price Target	Rating	Analyst
6/13/2024	$7.00	Buy	Rodman & Renshaw
4/23/2024	$6.00	Overweight	CapitalOne
3/13/2024	$4.00 → $5.00	Buy	Needham

More analyst ratings

$HRTX
Press Releases

Fastest customizable press release news feed in the world

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launchCMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of careSAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended
11/12/24 7:55:00 AM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera
11/4/24 5:00:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the In
10/29/24 4:05:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care

$HRTX
Leadership Updates

Live Leadership Updates

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera
11/4/24 5:00:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to
9/3/24 8:00:00 AM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years of experience in a variety of finance and accounting positions, including over a decade in the pharma industry. "I am excited to welcome Ira to Heron as Chief Financial Officer," said Craig Collard, Chief Executive Officer of Heron. "I had the pleasure of previously working with Ira and I look forward to her contribut
6/23/23 4:05:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care

$HRTX
Financials

Live finance-specific insights

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launchCMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of careSAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended
11/12/24 7:55:00 AM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the In
10/29/24 4:05:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act")SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success. We are improvi
8/6/24 4:05:00 PM ET
$HRTX
Biotechnology: Pharmaceutical Preparations
Health Care

Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use

Chat with this insight

Recent Analyst Ratings for $HRTX

$HRTX SEC Filings

SEC Form 10-Q filed by Heron Therapeutics Inc.

Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Heron Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$HRTX Market Insights

Live Market Insights

Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use

Heron Therapeutics shares are trading lower. The company announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement application for ZYNRELEF.

Heron Therapeutics Announces The FDA Acknowledged The Receipt Of The Company's Prior Approval Supplement Application For ZYNRELEF

$HRTX Press Releases

Fastest customizable press release news feed in the world

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

$HRTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Heron Therapeutics Inc.

SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

$HRTX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

FDA Approval for APONVIE issued to HERON THERAPS INC

FDA Approval for CINVANTI issued to HERON THERAPS INC

$HRTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

CapitalOne initiated coverage on Heron Therapeutics with a new price target

Needham reiterated coverage on Heron Therapeutics with a new price target

$HRTX Leadership Updates

Live Leadership Updates

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

$HRTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kaseta Michael was granted 37,879 shares (SEC Form 4)

SEC Form 3 filed by new insider Kaseta Michael

EVP, Chief Financial Officer Duarte Ira converted options into 3,874 shares, increasing direct ownership by 4% to 108,001 units (SEC Form 4)

$HRTX Financials

Live finance-specific insights

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

$HRTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

Forbes William P bought $46,995 worth of shares (50,000 units at $0.94), increasing direct ownership by 1,250% to 54,000 units (SEC Form 4)

Collard Craig A bought $137,970 worth of shares (150,000 units at $0.92), increasing direct ownership by 411% to 186,496 units (SEC Form 4)

Recent Analyst Ratings for
$HRTX

$HRTX
SEC Filings

$HRTX
Market Insights

$HRTX
Press Releases

$HRTX
Large Ownership Changes

$HRTX
FDA approvals

$HRTX
Analyst Ratings

$HRTX
Leadership Updates

$HRTX
Insider Trading

$HRTX
Financials

$HRTX
Insider Purchases